{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:59Z","timestamp":1787009459198,"version":"build-2736575974"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173260"],"award-info":[{"award-number":["82173260"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972708"],"award-info":[{"award-number":["81972708"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072681"],"award-info":[{"award-number":["82072681"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003082"],"award-info":[{"award-number":["82003082"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203651"],"award-info":[{"award-number":["82203651"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Technical Standard Program","award":["21DZ2201100"],"award-info":[{"award-number":["21DZ2201100"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>IDH1 mutations are causal in tumor development and progression; however, their association with disease characteristics, prognosis, and therapy response in patients with resected intrahepatic cholangiocarcinoma (ICC) remains controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>In this cohort study, we recruited 803 patients who underwent curative resection for ICC at a single hospital in China. We performed whole-exome sequencing and Sanger sequencing to identify IDH1 mutations. We used the Kaplan\u2013Meier method and log-rank test to compare overall survival (OS) and disease-free survival (DFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 5 different subtypes of IDH1 somatic mutation affecting 94 (11.7%) patients were identified. R132C was the most frequent mutant allele in this cohort, followed by R132L and R132G. Across all patients considered, those that received adjuvant chemotherapy had significantly superior OS and DFS compared with those that did not receive adjuvant chemotherapy. In the whole ICC cohort, patients with IDH1 mutations showed no significant difference in OS compared with patients with wild-type IDH1. When we looked at patients that either received or did not receive adjuvant chemotherapy separately, univariate and multivariable analyses revealed that IDH1 mutations were significantly associated with superior OS among patients that received adjuvant chemotherapy, whereas they were marginally associated with worse OS among patients that did not receive adjuvant chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We characterized the distribution of IDH1 mutations in a large cohort of patients with ICC from China. The presence of IDH1 mutations was associated with better survival and decreased risk of recurrence in patients with resected ICC that received adjuvant chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag124","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T11:39:47Z","timestamp":1775302787000},"source":"Crossref","is-referenced-by-count":1,"title":["Association of\n                    <i>IDH1<\/i>\n                    mutations with survival and recurrence in resected intrahepatic cholangiocarcinoma received or not received adjuvant chemotherapy"],"prefix":"10.1093","volume":"31","author":[{"given":"Pengcheng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]},{"name":"Liver Cancer Institute, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]},{"name":"Institute for Ovarian Cancer, Fudan University & Department of Gynecologic Oncology, Cancer Center, Fudan University Zhongshan Hospital , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]},{"name":"Liver Cancer Institute, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]},{"name":"Liver Cancer Institute, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Pu","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]},{"name":"Liver Cancer Institute, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongqi","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]},{"name":"Liver Cancer Institute, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chubin","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]},{"name":"Liver Cancer Institute, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]},{"name":"Liver Cancer Institute, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Liver Cancer Institute, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]},{"name":"Liver Cancer Institute, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixue","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]},{"name":"Liver Cancer Institute, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]},{"name":"Liver Cancer Institute, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8526-5221","authenticated-orcid":false,"given":"Shaolai","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]},{"name":"Liver Cancer Institute, Zhongshan Hospital, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"2026042618471822100_oyag124-B1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026042618471822100_oyag124-B2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jamasurg.2021.5679","article-title":"Association of KRAS variant subtypes with survival and recurrence in patients with surgically treated intrahepatic cholangiocarcinoma","volume":"157","author":"Zhou","year":"2022","journal-title":"JAMA Surg"},{"key":"2026042618471822100_oyag124-B3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"2026042618471822100_oyag124-B4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026042618471822100_oyag124-B5","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A randomized phase III study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026042618471822100_oyag124-B6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"key":"2026042618471822100_oyag124-B7","doi-asserted-by":"publisher","first-page":"101936","DOI":"10.1016\/j.ctrv.2019.101936","article-title":"Current standards and future perspectives in adjuvant treatment for biliary tract cancers","volume":"84","author":"Lamarca","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"2026042618471822100_oyag124-B8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"2026042618471822100_oyag124-B9","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science (1979)"},{"key":"2026042618471822100_oyag124-B10","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"key":"2026042618471822100_oyag124-B11","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1038\/leu.2015.91","article-title":"Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms","volume":"29","author":"Molenaar","year":"2015","journal-title":"Leukemia"},{"key":"2026042618471822100_oyag124-B12","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"2026042618471822100_oyag124-B13","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"key":"2026042618471822100_oyag124-B14","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41388-017-0077-z","article-title":"Wild-type and mutated IDH1\/2 enzymes and therapy responses","volume":"37","author":"Molenaar","year":"2018","journal-title":"Oncogene"},{"key":"2026042618471822100_oyag124-B15","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-16-2628","article-title":"Correlation between isocitrate dehydrogenase gene aberrations and prognosis of patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"23","author":"Xu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026042618471822100_oyag124-B16","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"2026042618471822100_oyag124-B17","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1634\/theoncologist.2015-0210","article-title":"Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma","volume":"20","author":"Goyal","year":"2015","journal-title":"Oncologist"},{"key":"2026042618471822100_oyag124-B18","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1245\/s10434-014-3828-x","article-title":"Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets","volume":"21","author":"Zhu","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"2026042618471822100_oyag124-B19","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat Genet"},{"key":"2026042618471822100_oyag124-B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001946","article-title":"Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3","volume":"9","author":"Zhou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026042618471822100_oyag124-B21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00292-006-0834-1","article-title":"[Pitfalls in the classification of liver tumors]. Pitfalls in der Klassifikation von Lebertumoren","volume":"27","author":"Wittekind","year":"2006","journal-title":"Pathologe"},{"key":"2026042618471822100_oyag124-B22","doi-asserted-by":"publisher","first-page":"103026","DOI":"10.1016\/j.amsu.2021.103026","article-title":"STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery","volume":"72","author":"Mathew","year":"2021","journal-title":"Ann Med Surg (Lond)"},{"key":"2026042618471822100_oyag124-B23","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/hep.30630","article-title":"A positive feedback loop between cancer stem-like cells and tumor-associated neutrophils controls hepatocellular carcinoma progression","volume":"70","author":"Zhou","year":"2019","journal-title":"Hepatology"},{"key":"2026042618471822100_oyag124-B24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41392-021-00838-3","article-title":"Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026042618471822100_oyag124-B25","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-Mutant molecular profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell Rep"},{"key":"2026042618471822100_oyag124-B26","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: Potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026042618471822100_oyag124-B27","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"2026042618471822100_oyag124-B28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","article-title":"Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma","volume":"40","author":"Dong","year":"2022","journal-title":"Cancer Cell"},{"key":"2026042618471822100_oyag124-B29","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/hep.32164","article-title":"Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma","volume":"75","author":"Zhou","year":"2022","journal-title":"Hepatology"},{"key":"2026042618471822100_oyag124-B30","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1212\/WNL.0b013e3181f96282","article-title":"IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas","volume":"75","author":"Houillier","year":"2010","journal-title":"Neurology"},{"key":"2026042618471822100_oyag124-B31","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/neuonc\/not198","article-title":"Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry","volume":"16","author":"Tran","year":"2014","journal-title":"Neuro Oncol"},{"key":"2026042618471822100_oyag124-B32","doi-asserted-by":"publisher","first-page":"fj201800547R","DOI":"10.1096\/fj.201800547R.","article-title":"IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity","volume":"32","author":"Khurshed","year":"2018","journal-title":"FASEB J"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag124\/67936490\/oyag124.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag124\/67936490\/oyag124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag124\/67936490\/oyag124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T22:47:22Z","timestamp":1777243642000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag124\/8626975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag124","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,7]]},"article-number":"oyag124"}}